中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.025 seconds)

    ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION
    4.
    发明申请
    ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION 审中-公开

    公开(公告)号：WO2018148113A1

    公开(公告)日：2018-08-16

    申请号：PCT/US2018/016573

    申请日：2018-02-02

    Applicant: STC.UNM

    Inventor： TIMMINS, Graham ,  DERETIC, Vojo P.

    IPC: C07B59/00 ,  C07C213/08 ,  C07C215/68 ,  A61K31/136 ,  A61K51/04 ,  A61P11/00 ,  A61P31/04

    Abstract: The present invention is directed to 13 C and/or 2 H isotope enhanced ambroxol ("isotope enhanced ambroxol") and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced amhroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and/or condition), especially an antophagy mediated disease state and/or condition which occurs in the lungs, for example, a Mycobacterium infection. Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer (small cell and non-small cell lung cancer, among other disease states and/or conditions, especially of the lung. Methods of treating autophagy disease states and/or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. An additional embodiment includes methods of synthesizing compounds according to the present invention as otherwise disclosed herein.

    BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS
    5.
    发明申请
    BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS 审中-公开
    用于感染MYCOBACTERIUM的药物治疗药物

    公开(公告)号：WO2015126930A2

    公开(公告)日：2015-08-27

    申请号：PCT/US2015/016359

    申请日：2015-02-18

    Applicant: STC.UNM

    Inventor： TIMMINS, Graham ,  CHOI, Seong, Won

    IPC: A61K31/425

    CPC classification number: A61K31/16 ,  A61K9/0075 ,  A61K31/4965 ,  A61K45/06 ,  A61K2300/00

    Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering to the subject a therapeutically effective amount of a urease inhibitor, optionally in combination with one or more anti-mycobacterial agents.

    Abstract translation: 在一个实施方案中，本发明提供了治疗患有或被怀疑患有分枝杆菌感染的受试者的方法，所述方法包括向受试者施用治疗有效量的脲酶抑制剂，任选地与一种 或更多的抗分枝杆菌剂。

    ANALYSIS OF P. AERUGINOSA INFECTION IN PATIENTS
    8.
    发明申请
    ANALYSIS OF P. AERUGINOSA INFECTION IN PATIENTS 审中-公开
    患者中阿维菌素感染的分析

    公开(公告)号：WO2008134026A1

    公开(公告)日：2008-11-06

    申请号：PCT/US2008/005412

    申请日：2008-04-25

    Applicant: STC.UNM ,  TIMMINS, Graham ,  DERETIC, Vojo, P.

    Inventor： TIMMINS, Graham ,  DERETIC, Vojo, P.

    IPC: C12Q1/00 ,  G01N33/554

    CPC classification number: C12Q1/04 ,  A61K51/04 ,  A61K51/0406 ,  A61K51/1206 ,  G01N33/497 ,  G01N2333/21

    Abstract: The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.

    Abstract translation: 本发明涉及用于检测铜绿假单胞菌感染风险的患者肺部铜绿假单胞菌感染和细菌负担的方法，特别是包括囊性纤维化（CF）患者。 本方法提供了许多试验（呼吸，血液，尿液），其易于对患者施用，其将敏感且特异性地检测肺部感染铜绿假单胞菌（粘液样和非粘液样）的存在和程度，并允许监测细菌 负载作为监测治疗的参数。

    REPURPOSING CANCER DRUGS FOR TREATMENT OF MYCOBACTERIUM
    9.
    发明申请
    REPURPOSING CANCER DRUGS FOR TREATMENT OF MYCOBACTERIUM 审中-公开
    回收癌症药物治疗细菌

    公开(公告)号：WO2018022494A1

    公开(公告)日：2018-02-01

    申请号：PCT/US2017/043481

    申请日：2017-07-24

    Applicant: STC.UNM

    Inventor： TIMMINS, Graham ,  LIU, Ke Jian Jim ,  ZHOU, Xixi

    IPC: A61K31/395 ,  A61K45/06 ,  A61P31/06

    Abstract: The present invention is directed to the discovery that pyrazinamide, a potent anti-tuberculosis agent acts through an entirely unexpected mechanism- through inhibition of the host enzyme poly ADP ribose polymerase ("PARP"). Thus, the present invention is directed to methods of treating: mycobacterial infections ( Mycobacterium ), especially M. tuberculosis using a PARP inhibitor, optionally in combination with at least one additional agent useful in the treatment of a mycobacterial infection, especially tuberculosis. Pharmaceutical compositions, especially including a pharmaceutical composition in oral or inhalation dosage form, comprising a PARP inhibitor, optionally in combination with an additional anti-mycobacterial agent, especially an additional anti-tuberculosis agent represent additional embodiments of the present invention.

    Abstract translation: 本发明涉及通过抑制宿主酶多聚ADP核糖聚合酶（“PARP”）而发现吡嗪酰胺（一种有效的抗结核剂）通过完全意想不到的机制起作用。 因此，本发明涉及治疗：分枝杆菌感染（分枝杆菌），特别是M的方法。 任选地与至少一种可用于治疗分枝杆菌感染，特别是结核病的其他药剂组合使用。 包含PARP抑制剂的药物组合物，特别是包含口服或吸入剂型的药物组合物，任选地与另外的抗分枝杆菌剂，特别是另外的抗结核剂组合，代表本发明的另外的实施方案。

Patent Agency Ranking